Navigation Links
Alexza's Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
Date:5/15/2008

MOUNTAIN VIEW, Calif., May 15 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate presentation will be webcast live during the Seventh Annual JMP Securities Research Conference on Monday, May 19, 2008 at 11:30 a.m. Eastern Time and at the Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008 at 2:00 p.m. Eastern Time.

The JMP presentation will be webcast from The Ritz-Carlton Hotel in San Francisco. To access the live presentation via the Web, please go to the Investor Relations tab at http://www.alexza.com or at http://www.wsw.com/webcast/jmp6/alxa/.

The Citi Investment will be webcast from the Hilton New York Hotel in San New York. To access the live presentation via the Web, please go to the Investor Relations tab at http://www.alexza.com or at http://www.veracast.com/webcasts/citigroup/healthcare08/31112361.cfm.

A replay of each webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ardea Biosciences Announces Upcoming Corporate Meetings
2. Direct Reliefs Corporate Partners Key to Aiding Cyclone Victims
3. Aflac Incorporated to Webcast 2008 Financial Analysts Briefing
4. Health Care Corporate Compliance Certificate Program to Be Offered at Hamline University School of Laws Health Law Institute
5. GSK Announces Changes to Corporate Executive Team
6. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
7. Government and Corporate Support Together Help Africans Battling Malaria, AIDS
8. Accuray Incorporateds CEO to Present at Morgan Stanley 2008 Global Healthcare Unplugged Conference
9. Aflac Incorporated Announces First Quarter Results, Declares Second Quarter Cash Dividend
10. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
11. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017   Divoti USA ... Jewelry up to the standard of the latest FDA requirements, which ... 2017). Anyone in need of Medical ID jewelry such ... Alert Jewelry are engraved in terms of the new ... Divoti offers ...
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
Breaking Medicine Technology: